Anaemia, a common but often unrecognized risk in diabetic patients: A review

Diabetes and Metabolism

Volumn 41, Issue 1, 2015, Pages 18-27

  Angelousi, A ^a,c   Larger, E ^a,b  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NONE   (Greece)

Author keywords

ACE inhibitors; Addison's disease; Anaemia; B12; Coeliac disease; Diabetes; Erythropoietin; Ferritin; G6PD; Gastritis; Hypogonadism; Hypothyroidism; Metformin; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; METFORMIN;

ADDISON DISEASE; ANEMIA; CELIAC DISEASE; CHRONIC INFLAMMATION; CYANOCOBALAMIN DEFICIENCY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; GASTRITIS; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HASHIMOTO DISEASE; HEMOLYSIS; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INSULIN RESISTANCE; IRON DEFICIENCY; KIDNEY FAILURE; MEGALOBLASTIC ANEMIA; MICROANGIOPATHY; PERNICIOUS ANEMIA; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA; COMPLICATION; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADDISON DISEASE; ANEMIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOTHYROIDISM; VITAMIN B 12 DEFICIENCY;

EID: 84921848350     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2014.06.001     Document Type: Review

References (106)

1. World Health Organization Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968, 405:5-37.
2. Macdougall I.C., Eckardt K.U., Locatelli F. Latest US KDOQI Anaemia Guidelines update-What are the implications for Europe?. Nephrol Dial Transplant 2007, 22:2738-2742.
3. Thomas M.C., Tsalamandris C., MacIsaac R.J., Jerums G. The epidemiology of hemoglobin levels in patients with type 2 diabetes. Am J Kidney Dis 2006, 48:537-545.
4. Ezenwaka C.E., Jones-Lecointe A., Nwagbara E., Seales D., Okali F. Anaemia and kidney dysfunction in Caribbean type 2 diabetic patients. Cardiovasc Diabetol 2008, 27(7):25.
5. Goldhaber A., Ness-Abramof R., Ellis M.H. Prevalence of anaemia among unselected adults with diabetes mellitus and normal serum creatinine levels. Endocr Pract 2009, 15:714-719.
6. Grossman C., Dovrish Z., Koren-Morag N., Bornstein G., Leibowitz A. Diabetes mellitus with normal renal function is associated with anaemia. Diabetes Metab Res Rev 2014, 30:291-296.
7. Thomas M.C., MacIsaac R.J., Tsalamandris C., Power D., Jerums G. Unrecognized anaemia in patients with diabetes: a cross-sectional survey. Diabetes Care 2003, 26:1164-1169.
8. Astor B.C., Muntner P., Levin A., Eustace J.A., Coresh J. Association of kidney function with anaemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2002, 162:1401-1408.
9. Thomas M.C., MacIsaac R.J., Tsalamandris C., Molyneaux L., Goubina I., Fulcher G., et al. The burden of anaemia in type 2 diabetes and the role of nephropathy: a cross-sectional audit. Nephrol Dial Transplant 2004, 19:1792-1797.
10. Thomas M.C., Viberti G., Groop P.H. Screening for chronic kidney disease in patients with diabetes: are we missing the point?. Nat Clin Pract Nephrol 2008, 4:2-3.
11. Singh D.K., Winocour P., Farrington K. Erythropoietic stress and anaemia in diabetes mellitus. Nat Rev Endocrinol 2009, 5:204-210.
12. Mohanram A., Zhang Z., Shahinfar S., Keane W.F., Brenner B.M., Toto R.D. Anaemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004, 66:1131-1138.
13. New R.P., Hegarty J., Gibson J.M., O'Donoghue D.J., Buchan I.E. The high prevalence of unrecognized anaemia in patients with diabetes and chronic kidney disease: a population-based study. Diabet Med 2008, 25:564-569.
14. Mehdi U., Toto R.D. Anaemia, diabetes, and chronic kidney disease. Diabetes Care 2009, 32:1320-1326.
15. Craig K.J., Williams J.D., Riley S.G., Smith H., Owens D.R., Worthing D., et al. Anaemia and diabetes in the absence of nephropathy. Diabetes Care 2005, 28:1118-1123.
16. Bosman D.R., Winkler A.S., Marsden J.T., Macdougall I.C., Watkins P.J. Anaemia witherythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001, 24:495-499.
17. Winkler A.S., Marsden J., Chaudhuri K.R., Hambley H., Watkins P.J. Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 1999, 16:813-819.
18. Mojiminiyi O.A., Abdella N.A., Zaki M.Y., El Gebely S.A., Mohamedi H.M. AldhahiWA. Prevalence and associations of low plasma erythropoietin in patients with diabetes mellitus type 2. Diabet Med 2006, 23:839-844.
19. Fioretto P., Mauer M., Brocco E., Velussi M., Frigato F., Muollo B., et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1997, 39:1569-1576.
20. Komers R., Anderson S. Paradoxes of nitric oxide in the diabetic kidney. Am J Physiol Renal Physiol 2003, 284:1121-1137.
21. Catrina S.B., Okamoto K., Pereira T., Brismar K., Poellinger L. Hyperglycaemia regulates hypoxia-inducible factor-1alpha protein stability and function. Diabetes 2004, 53:3226-3232.
22. Semenza G.L. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009, 114:2015-2019.
23. Larger E., Marre M., Corvol P., Gasc J.M. Hyperglycaemia-induced defects in angiogenesis in the chicken chorioallantoic membrane model. Diabetes 2004, 53:752-761.
24. Dikow R., Schwenger V., Schömig M., Ritz E. How should we manage anaemia in patients with diabetes?. Nephrol Dial Transplant 2002, 17:67-72.
25. Skali H., Lin J., Pfeffer M.A., Chen C.Y., Cooper M.E., McMurray J.J., et al. Hemoglobin stability in patients with anaemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis 2013, 61:238-246.
26. Means R.T., Krantz S.B. Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood 1992, 80:1639-1647.
27. Dai C.H., Price J.O., Brunner T., Krantz S.B. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998, 91:1235-1242.
28. Cohen R.M., Franco R.S., Khera P.K., Smith E.P., Lindsell C.J., Ciraolo P.J., et al. Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008, 112:4284-4291.
29. Wautier J.L., Wautier M.P., Schmidt A.M., Anderson G.M., Hori O., Zoukourian C., et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 1994, 91:7742-7746.
30. Facchini F.S., Carantoni M., Jeppesen J., Reaven G.M. Hematocrit and hemoglobin are independently related to insulin resistance and compensatory hyperinsulinemia in healthy, non-obese men and women. Metabolism 1998, 47:831-835.
31. McCarty M.F. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1alpha. Med Hypotheses 2003, 61:567-573.
32. Masuda S., Chikuma M., Sasaki R. Insulin-like growth factors and insulin stimulate erythropoietin production in primary cultured astrocytes. Brain Res 1997, 746:63-70.
33. Susa J.B., Schwartz R. Effects of hyperinsulinemia in the primate fetus. Diabetes 1985, 2:36-41.
34. Widness J.A., Teramo K.A., Clemons G.K., Voutilainen P., Stenman U.H., McKinlay S.M., et al. Direct relationship of antepartum glucose control and foetal erythropoietin in human type 1 (insulin-dependent) diabetic pregnancy. Diabetologia 1990, 33:378-383.
35. Sam A.H., Busbridge M., Amin A., Webber L., White D., Franks S., et al. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome. Diabet Med 2013, 30:1495-1499.
36. Wang H., Li H., Jiang X., Shi W., Shen Z., Li M. Hepcidin is directly regulated by insulin and plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes 2014, 63:1506-1518.
37. Carette C., Dubois-Laforgue D., Gautier J.F., Timsit J. Diabetes mellitus and glucose-6-phosphate dehydrogenase deficiency: from one crisis to another. Diabetes Metab 2011, 37:79-82.
38. Chanmugan D., Frumin A.M. Abnormal oral glucose tolerance response in erythrocyte G6PD deficiency. N Engl J Med 1964, 271:1202-1204.
39. Nwose E.U., Jelinek H.F., Richards R.S., Kerr P.G. Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications. Br J Biomed Sci 2007, 64:35-43.
40. West I.C. Radicals and oxidative stress in diabetes. Diabet Med 2000, 17(3):171-180.
41. Saha N. Association of glucose-6-phosphate dehydrogenase deficiency with diabetes mellitus in ethnic groups of Singapore. J Med Genet 1979, 16:431-434.
42. Niazi G.A. Glucose-6-phosphate dehydrogenase deficiency and diabetes mellitus. Int J Hematol 1991, 54:295-298.
43. Saeed T.K., Hamamy H.A., Alwan A.A. Association of glucose-6-phosphate dehydrogenase deficiency with diabetes mellitus. Diabet Med 1985, 2:110-112.
44. Zhang Z., Liew C.W., Handy D.E., Leopold J.A., Hu J., Guo L., et al. High glucose inhibits glucose-6-phosphate dehydrogenase, leading to increased oxidative stress and beta-cell apoptosis. FASEB J 2010, 24:1497-1505.
45. Carmel R. Prevalence of undiagnosed pernicious anaemia in the elderly. Arch Intern Med 1996, 156:1097-1100.
46. De Block C.E., De Leeuw I.H., Van Gaal L.F. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J Clin Endocrinol Metab 1999, 84:4062-4067.
47. De-Block C., De-Leeuw I., Rooman R., Winnock F., Du-Caju M., Van-Gaal L: Gastric parietal cell antibodies are associated with glutamic acid decarboxylase-65 antibodies and the HLA DQA1*0501-DQB1*0301 haplotype in type 1 diabetes. Diabet Med 2000, 17:618-622.
48. De-Block C., De-Leeuw H., Van-Gaal L. Autoimmune Gastritis in Type 1 Diabetes: A Clinically Oriented Review. J Clin Endocrinol Metab 2008, 12:363-371.
49. Toh B.H., Sentry J.W., Alderuccio F. The causative H+/K+ATPase antigen in the pathogenesis of autoimmune gastritis. Immunol Today 2000, 21:348-354.
50. Amedei A., Bergman M.P., Appelmelk B.J., Azzurri A., Benagiano M., Tamburini C., et al. Molecular mimicry between Helicobacter pylori antigens and H+, K+-adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003, 198:1147-1156.
51. Bergman M.P., Amedei A., D'Elios M.M., Azzurri A., Benagiano M., Tamburini C., et al. Characterization of H+, K+-ATPaseT cell epitopes in human autoimmune gastritis. Eur J Immunol 2003, 33:539-545.
52. Fujimoto S., Kawakami N., Ohara A. Non enzymatic glycation of transferring;decrease of iron binding capacity and increase of oxygen radical production. Biol Pharm Bull 1995, 18:396-400.
53. Kibirige D., Mwebaze R. Vitamin B12 deficiency among patients with diabetes mellitus: is routine screening and supplementation justified?. J Diabetes Metab Disord 2013, 12:17.
54. Armbrecht U., Stockbrügger R.W., Rode J., Menon G.G., Cotton P.B. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow-up study of 80 patients. Gut 1990, 31:1105-1109.
55. De Block C.E., Colpin G., Thielemans K., Coopmans W., Bogers J.J., Pelckmans P.A., et al. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes. Diabetes Care 2004, 27:1387-1393.
56. Fernández-Bañares F., Monzón H., Forné M. A short review of malabsorption and anaemia. World J Gastroenterol 2009, 15:4644-4652.
57. Lauret E., Rodrigo L. Celiac disease and autoimmune-associated conditions. Biomed Res Int 2013, 2013:127589.
58. Sollid L.M., Qiao S.W., Anderson R.P., Gianfrani C., Koning F. Nomenclature and listing of celiac disease relevant gluten T-cell epitopes restricted by HLA-DQ molecules. Immunogenetics 2012, 64:455-460.
59. Dieterich W., Ehnis T., Bauer M., Donner P., Volta U., Riecken E.O., et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997, 3:797-801.
60. Fallang L.E., Bergseng E., Hotta K., Berg-Larsen A., Kim C.Y., Sollid L.M. Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation. Nat Immunol 2009, 10:1096-1101.
61. Aggarwal S., Lebwohl B., Green P.H. Screening for celiac disease in average-risk and high-risk populations. Therap Adv Gastroenterol 2012, 5:37-47.
62. Cerutti F., Bruno G., Chiarelli F., Lorini R., Meschi F., Sacchetti C. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 2004, 27:1294-1298.
63. Mahmud F.H., Murray J.A., Kudva Y.C., Zinsmeister A.R., Dierkhising R.A., Lahr B.D., et al. Celiac disease in type 1 diabetes mellitus in a North American community: prevalence, serologic screening, and clinical features. Mayo Clin Proc 2005, 80:1429-1434.
64. Ludvigsson J.F., Ludvigsson J., Ekbom A., Montgomery S.M. Celiac disease and risk of subsequent type 1 diabetes: a general population cohort study of children and adolescents. Diabetes Care 2006, 29:2483-2488.
65. Bakker S.F., Tushuizen M.E., Stokvis-Brantsma W.H., et al. Frequent delay of coeliac disease diagnosis in symptomatic patients with type 1 diabetes mellitus: clinical and genetic characteristics. Eur J Intern Med 2013, 24:456-460.
66. Popovic W.J., Brown J.E., Adamson J.W. The influence of thyroid hormones on in vitro erythropoiesis. Mediation by a receptor with beta adrenergic properties. J Clin Invest 1977, 60:907-913.
67. Erdogan M., Kösenli A., Ganidagli S., Kulaksizoglu M. Characteristics of anaemia in subclinical and overt hypothyroid patients. Endocr J 2012, 59:213-220.
68. Christ-Crain M., Meier C., Huber P., Zulewski H., Staub J.J., Müller B. Effect of restoration of euthyroidism on peripheral blood cells and erythropoietin in women with subclinical hypothyroidism. Hormones (Athens) 2003, 2:237-242.
69. Van den Driessche A., Eenkhoorn V., Van Gaal L., De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009, 67:376-387.
70. Ferrucci L., Maggio M., Bandinelli S., Basaria S., Lauretani F., Ble A., et al. Low testosterone levels and the risk of anaemia in older men and women. Arch Intern Med 2006, 166:1380-1388.
71. Carrero J.J., Bárány P., Yilmaz M.I., Qureshi A.R., Sonmez A., Heimbürger O., et al. Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease. Nephrol Dial Transplant 2012, 27:709-715.
72. Ornstein D.K., Beiser J.A., Andriole G.L. Anaemia in men receiving combined Finasteride and flutamide therapy for advanced prostate cancer. BJU Int 1999, 83:43-46.
73. Strum S.B., McDermed J.E., Scholz M.C., Johnson H., Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997, 79:933-941.
74. Bhatia V., Chaudhuri A., Tomar R., Dhindsa S., Ghanim H., Dandona P. Low testosterone and high C-reactive protein concentrations predict low hematocrit in T2D. Diabetes Care 2006, 29:2289-2294.
75. Grossmann M., Panagiotopolous S., Sharpe K., MacIsaac R.J., Clarke S., Zajac J.D., et al. Low testosterone and anaemia in men with T2D. Clin Endocrinol (Oxf) 2009, 70:547-553.
76. Carruthers M., Trinick T.R., Jankowska E., Traish A.M. Are the adverse effects of glitazones linked to induced testosterone deficiency?. Cardiovasc Diabetol 2008, 7:30.
77. Ting R., Szeto C., Chan M., Ma K., Chow K. Risk Factors of Vitamin B12 Deficiency in Patients Receiving Metformin. Arch Intern Med 2006, 12:1975-1979.
78. Bauman W., Shaw S., Jayatilleke E., Spungen A., Herbert V: Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 2000, 23:1227-1231.
79. Pierce S.A., Chung A.H., Black K.K. Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy. Ann Pharmacother 2012, 46:1470-1476.
80. Filioussi K., Bonovas S., Katsaros T. Should we screen diabetic patients using biguanides for megaloblastic anaemia?. Aust Fam Physician 2003, 32:383-384.
81. Mazokopakis E., Starakis I: Recommendations for diagnosis and management of metformin-induced vitamin B12 (Cbl) deficiency. Diabetes Res Clin Pract 2012, 97:359-367.
82. Snow C. Laboratory Diagnosis of vitamin B12 and folate deficiency.A guide for the primary care physician. Arch Intern Med 1999, 12:1289-1298.
83. Meir A., Kleinman Y., Rund D., Da'as N. Metformin-induced haemolyticanaemia in a patient with glucose-6- phosphate dehydrogenase deficiency. Diabetes Care 2003, 26:956-957.
84. Blum A., Ghaben W., Slonimsky G., Simsolo C. Metformin-induced haemolyticanaemia. Isr Med Assoc J 2011, 13:444-445.
85. Kashyap A.S., Kashyap S. Haemolytic anaemia due to metformin. Postgrad Med J 2000, 76:125-126.
86. Lin K.D., Lin J.D., Juang J.H. Metformin-induced hemolysis with jaundice. N Engl J Med 1998, 339:1860-1861.
87. Berria R., Glass L., Mahankali A., Miyazaki Y., Monroy A., De Filippis E., et al. Reduction in hematocrit and haemoglobinfollowing pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007, 82:275-281.
88. Chilcott J., Tappenden P., Jones M.L., Wight J.P. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001, 23:1792-1823.
89. Kuzuya T., Iwamoto Y., Kosaka K., Takebe K., Yamanouchi T., Kasuga M., et al. A pilot clinical trial of a new oral hypoglycaemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1991, 11:147-153.
90. Henry R.R., Lincoff A.M., Mudaliar S., Rabbia M., Chognot C., Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009, 374:126-135.
91. Lang K.S., Lang P.A., Bauer C., Duranton C., Wieder T., Huber S.M., et al. Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem 2005, 15:195-202.
92. Cheng J., Nakamura H., Imanishi H., Liu W., Morisaki T., Sugiyama T., et al. Peroxisome proliferator-activated receptor gamma ligands, 15-deoxy-Delta12,14-prostaglandin J2, and ciglitazone, induce growth inhibition and cell cycle arrest in hepatic oval cells. Biochem Biophys Res Commun 2004, 322:458-464.
93. Guan Y., Hao C., Cha D.R., Rao R., Lu W., Kohan D.E., et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861-866.
94. Deldar A., Williams G., Stevems C. Pathogenesis of thiazolidinedione induced hematotoxicity in the dog. Diabetes 1993, 42:179.
95. Hirase N., Yanase T., Mu Y., Muta K., Umemura T., Takayanagi R., et al. Thiazolidinedione suppresses the expression of erythroid phenotype in erythroleukemia cell line K562. Leuk Res 2000, 24:393-400.
96. Nagasawa E., Abe Y., Nishimura J., Yanase T., Nawata H., Muta K. Pivotal role ofperoxisome proliferator-activated receptor gamma (PPARgamma) in regulation oferythroid progenitor cell proliferation and differentiation. Exp Hematol 2005, 33:857-864.
97. Meloni G., Meloni T. Glyburide-induced acute haemolysis in a G6PD-deficient patient with NIDDM. Br J Haematol 1996, 92:159-160.
98. Recker R.R., Hynes H.E. Pure red blood cell aplasia associated with chlorpropamide therapy. Patient summary and review of the literature. Arch Intern Med 1969, 123:445-447.
99. Marathias K.P., Agroyannis B., Mavromoustakos T., Matsoukas J. VlahakosDV. Hematocrit-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 2004, 4:483-486.
100. Vlahakos D.V., Marathias K.P., Madias N.E. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis 2010, 56:558-565.
101. Bacon B.R., Rothman S.A., Ricanati E.S., Rashad F.A. Renal artery stenosis witherythrocytosis after renal transplantation. Arch Intern Med 1980, 140:1206-1211.
102. Kuriyama S., Tomonari H., Tokudome G., Horiguchi M., Hayashi H., Kobayashi H., et al. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002, 25:849-855.
103. James S.H., Meyers A.M. Microangiopathic haemolytic anaemia as a complication of diabetes mellitus. Am J Med Sci 1998, 315:211-215.
104. Lippi G., Mercadanti M., Aloe R., Targher G. Erythrocyte mechanical fragility is increased in patients with type 2 diabetes. Eur J Intern Med 2012, 23:150-153.
105. Zmysłowska A., Młynarski W. Megaloblastic anaemia in infancy or early childhood and diabetes as leading symptoms of the TRMA syndrome. Pediatr Endocrinol Diabetes Metab 2012, 18:37-39.
106. Bay A., Keskin M., Hizli S., Uygun H., Dai A., Gumruk F. Thiamine-responsive megaloblastic anaemia syndrome. Int J Hematol 2010, 92:524-526.